Northstar Asset Management LLC raised its stake in shares of Celgene Corporation (NASDAQ:CELG) by 0.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 9,390 shares of the biopharmaceutical company’s stock after buying an additional 40 shares during the period. Northstar Asset Management LLC’s holdings in Celgene Corporation were worth $1,219,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Motco boosted its position in shares of Celgene Corporation by 306.9% in the first quarter. Motco now owns 822 shares of the biopharmaceutical company’s stock valued at $102,000 after buying an additional 620 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the first quarter valued at approximately $118,000. Carroll Financial Associates Inc. boosted its position in shares of Celgene Corporation by 70.9% in the first quarter. Carroll Financial Associates Inc. now owns 964 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 400 shares in the last quarter. Oakworth Capital Inc. boosted its position in shares of Celgene Corporation by 60.9% in the first quarter. Oakworth Capital Inc. now owns 1,089 shares of the biopharmaceutical company’s stock valued at $136,000 after buying an additional 412 shares in the last quarter. Finally, Acropolis Investment Management LLC acquired a new position in shares of Celgene Corporation during the second quarter valued at approximately $144,000. 78.34% of the stock is owned by institutional investors.

Shares of Celgene Corporation (NASDAQ CELG) traded up 0.05% during mid-day trading on Friday, hitting $127.65. 4,270,548 shares of the stock traded hands. Celgene Corporation has a 12-month low of $96.93 and a 12-month high of $139.00. The stock has a market cap of $99.87 billion, a P/E ratio of 39.53 and a beta of 1.89. The firm’s 50 day moving average price is $133.74 and its 200-day moving average price is $124.92.

Celgene Corporation (NASDAQ:CELG) last released its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.61 by $0.21. Celgene Corporation had a net margin of 21.35% and a return on equity of 68.51%. The business had revenue of $3.27 billion for the quarter, compared to analysts’ expectations of $3.23 billion. During the same quarter last year, the company earned $1.44 EPS. The company’s revenue for the quarter was up 18.7% compared to the same quarter last year. Analysts predict that Celgene Corporation will post $7.32 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “Northstar Asset Management LLC Acquires 40 Shares of Celgene Corporation (CELG)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/20/northstar-asset-management-llc-acquires-40-shares-of-celgene-corporation-celg.html.

Several equities analysts have commented on CELG shares. Credit Suisse Group set a $148.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Monday, May 22nd. Jefferies Group LLC set a $154.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. Vetr cut shares of Celgene Corporation from a “strong-buy” rating to a “buy” rating and set a $132.90 price target for the company. in a research report on Thursday, May 11th. BTIG Research reissued a “buy” rating and issued a $138.00 price target on shares of Celgene Corporation in a research report on Monday, May 1st. Finally, Cantor Fitzgerald set a $159.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, April 27th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, twenty-two have assigned a buy rating and one has assigned a strong buy rating to the stock. Celgene Corporation currently has an average rating of “Buy” and an average price target of $147.44.

In related news, Director Ernest Mario sold 18,506 shares of the stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the sale, the director now owns 69,424 shares of the company’s stock, valued at approximately $9,061,220.48. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Robert J. Hugin sold 175,970 shares of the stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $134.14, for a total transaction of $23,604,615.80. Following the completion of the sale, the insider now directly owns 1,033,909 shares in the company, valued at approximately $138,688,553.26. The disclosure for this sale can be found here. In the last ninety days, insiders sold 253,761 shares of company stock worth $33,792,445. Corporate insiders own 0.95% of the company’s stock.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.